Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 2a)

NCT04698642 is registered in ClinicalTrials.gov with Caliway Biopharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04698642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04698642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-stage, Phase 1/2a Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (Phase 2a)
Lead sponsor
Caliway Biopharmaceuticals Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 3, 2020
Completion date
November 12, 2020
Enrollment
43 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

subcutaneous fat